How should I manage a patient with marijuana use, sodium‑sensitive hypertension from primary hyperaldosteronism, and frequent migraines?

Management of Marijuana Use, Primary Hyperaldosteronism, and Migraines

In this patient with primary hyperaldosteronism causing sodium-sensitive hypertension and frequent migraines, initiate spironolactone 50-100 mg daily as first-line therapy—this single agent will simultaneously treat both the hyperaldosteronism and provide migraine prophylaxis, while counseling the patient that marijuana cessation may temporarily worsen blood pressure but is advisable given the uncertain cardiovascular effects. 1, 2

Primary Hyperaldosteronism Management

Diagnostic Confirmation and Subtype Classification

• Confirm the diagnosis of primary aldosteronism through aldosterone-to-renin ratio screening, followed by aldosterone suppression testing if not already completed 3
• Determine whether the hyperaldosteronism is unilateral (surgical candidate) or bilateral (medical management) through adrenal CT imaging and adrenal venous sampling 1, 3
• Perform a 1-mg overnight dexamethasone suppression test if an adrenal adenoma is present to exclude autonomous cortisol secretion 3

Medical Treatment Strategy

• Start spironolactone 50-100 mg once daily as the preferred mineralocorticoid receptor antagonist (MRA), titrating up to 300-400 mg daily if necessary to achieve blood pressure control 1, 3
• Monitor renin levels during MRA therapy—if hypertension remains uncontrolled and renin is suppressed, increase the spironolactone dose 3
• Consider eplerenone as an alternative if the patient develops gynaecomastia or erectile dysfunction (men), though it requires twice-daily dosing and is less potent than spironolactone 1
• If spironolactone is ineffective or not tolerated, consider adding a beta-blocker, followed by centrally acting agents, alpha-blockers, or other potassium-sparing diuretics 1

Migraine Management

Acute Treatment Protocol

• Prescribe NSAIDs as first-line acute therapy: ibuprofen 400-800 mg (preferred over 200 mg), diclofenac potassium, or aspirin 2, 4
• Instruct the patient to take medication early when headache is still mild for maximum effectiveness 2
• Limit NSAID use to fewer than 15 days per month to prevent medication overuse headache 2, 4
• Escalate to triptans (sumatriptan, rizatriptan, or eletriptan) when NSAIDs provide inadequate relief after 2-3 attempts, taken early while pain is mild 2, 4
• Limit triptan use to ≤10 days per month to avoid medication overuse headache 2, 4
• Avoid opioids or butalbital-containing compounds entirely for migraine treatment 4

Preventive Treatment Strategy

• The spironolactone prescribed for hyperaldosteronism will provide dual benefit, as it has documented efficacy for migraine prevention 2
• If migraines remain inadequately controlled on spironolactone alone (≥2 migraine days per month with significant disability), add a beta-blocker such as propranolol 80-240 mg/day or metoprolol, which will also help control hypertension 2
• Alternative first-line preventive options include amitriptyline 10-100 mg at night (especially if anxiety or depression coexist), venlafaxine, or candesartan (particularly useful given hypertension) 2
• Topiramate 50-100 mg daily can be considered if the patient is obese, though cognitive side effects, paresthesias, and fatigue are common 2
• Reserve CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) or CGRP antagonist-gepants (atogepant, rimegepant) only after trials of first-line agents have failed 2
• Assess efficacy of oral preventive medications after 2-3 months at therapeutic dose before switching 2

Marijuana Use Considerations

Cardiovascular Effects and Counseling

• Counsel the patient that abrupt cessation of daily cannabis use may cause clinically significant increases in blood pressure (up to 22.8 mm Hg systolic and 12.3 mm Hg diastolic in some individuals), which could temporarily worsen hypertension control 5
• Monitor blood pressure closely during the first 1-2 weeks if the patient attempts to quit cannabis, as the time course of this withdrawal effect is not well-established 5
• Long-term cumulative cannabis use does not appear to increase the risk of incident hypertension based on 35-year follow-up data, suggesting the acute withdrawal effect is temporary 6

Migraine Treatment Considerations

• While some observational data suggest cannabis may provide symptom relief for headache and migraine (94% of users reported relief with average reduction of 3.3 points on 0-10 scale), these studies lack rigorous controls and do not establish efficacy compared to evidence-based treatments 7, 8
• THC levels ≥10% appear to be the strongest predictor of symptom relief in observational studies, with greater effects in younger users and females 7
• Do not recommend cannabis as a primary migraine treatment given the lack of controlled trial data, potential for medication overuse patterns, and availability of proven evidence-based therapies 2, 7, 8
• If the patient insists on continuing cannabis use for migraines, emphasize that it should not replace evidence-based acute and preventive treatments, and monitor for medication overuse patterns 2

Monitoring and Follow-Up

Blood Pressure and Electrolyte Monitoring

• Monitor blood pressure, serum potassium, and renal function within 1-2 weeks of initiating spironolactone, then monthly until stable 1, 3
• Titrate spironolactone based on blood pressure response and renin levels—suppressed renin despite uncontrolled hypertension indicates need for dose escalation 3
• If the patient quits cannabis, increase blood pressure monitoring frequency during the first 2 weeks to detect withdrawal-related hypertension 5

Migraine Outcome Assessment

• Have the patient maintain a headache diary to track attack frequency, severity, and medication use 2
• Reassess migraine control after 2-3 months of preventive therapy at therapeutic dose 2
• Consider pausing preventive treatment after 6-12 months of successful control to determine if therapy can be stopped 2

Critical Pitfalls to Avoid

• Never allow the patient to increase acute migraine medication frequency in response to frequent attacks—instead, optimize preventive therapy 2
• Do not abandon spironolactone or other preventive treatments prematurely, as efficacy takes weeks to months to establish 2
• Avoid prescribing opioids or butalbital for migraine treatment, as these worsen long-term outcomes and increase medication overuse headache risk 4
• Do not rely solely on cannabis for migraine management given the lack of controlled efficacy data and availability of proven treatments 2, 7, 8
• Monitor for hyperkalemia when using spironolactone, particularly if adding other potassium-sparing agents or ACE inhibitors/ARBs 1, 3
• Failure of one preventive medication class does not predict failure of others—try different classes sequentially if initial therapy is inadequate 2